Cargando…

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor

Detalles Bibliográficos
Autores principales:	Vandeveer, Amanda, Fallon, Jonathan, Tighe, Robert, Sabzevari, Helen, Schlom, Jeffrey, Greiner, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645497/ http://dx.doi.org/10.1186/2051-1426-3-S2-P70

Ejemplares similares

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
por: Fallon, Jonathan K., et al.
Publicado: (2017)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
por: Chin, K., et al.
Publicado: (2017)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Analysis of errors in the structure determination of MsbA
por: Jeffrey, Philip D.
Publicado: (2009)

Transcriptional Network in Colletotrichum gloeosporioides Mutants Lacking Msb2 or Msb2 and Sho1
por: Liu, Na, et al.
Publicado: (2022)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Product review: avelumab, an anti-PD-L1 antibody
por: Collins, Julie M., et al.
Publicado: (2018)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
por: Rajan, Arun, et al.
Publicado: (2019)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer
por: Saad, Farouk Tijjani, et al.
Publicado: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

The GAP activity of Msb3p and Msb4p for the Rab GTPase Sec4p is required for efficient exocytosis and actin organization
por: Gao, Xiang-Dong, et al.
Publicado: (2003)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF
por: Hu, Zhiming, et al.
Publicado: (2010)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
por: Morillon, Y. Maurice, et al.
Publicado: (2019)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Conformational Motion of the ABC Transporter MsbA Induced by ATP Hydrolysis
por: Borbat, Peter P, et al.
Publicado: (2007)

Msb2 Shedding Protects Candida albicans against Antimicrobial Peptides
por: Szafranski-Schneider, Eva, et al.
Publicado: (2012)

Energetics of lipid transport by the ABC transporter MsbA is lipid dependent
por: Guo, Dawei, et al.
Publicado: (2021)

Structural basis for lipid and copper regulation of the ABC transporter MsbA
por: Lyu, Jixing, et al.
Publicado: (2022)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses
por: Wood, Laura S., et al.
Publicado: (2022)

A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer
por: Kokura, Kazuki, et al.
Publicado: (2023)

Editorial: Superficial Bladder Cancer
por: Kirkali, Ziya
Publicado: (2006)

Superficial Bladder Cancer Therapy
por: Schenkman, Emmanuel, et al.
Publicado: (2004)

The reconstituted Escherichia coli MsbA protein displays lipid flippase activity
por: Eckford, Paul D. W., et al.
Publicado: (2010)

ATP-dependent substrate transport by the ABC transporter MsbA is proton-coupled
por: Singh, Himansha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_olb4fjh21pmqv2i59781frjq6b